Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6010 ± SYH2051 ± bevacizumab in advanced solid tumors (Ib/II)
CTR20244350Phase 2Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Nov 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CPO301 in Nonhematologic neoplasms, sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Nov 2024; status: active.
02
Drugs
CPO301
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20244350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244350.